FDA approves pancreatic cancer drug Abraxane
US-based Celgene Corporation's chemotherapy drug Abraxane has received approval by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer, in combination with gemcitabine.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Abraxane | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Pancreas | Pancreatic Cancer | Pharmaceuticals